Vaxcyte (NASDAQ:PCVX) announced a long-term agreement worth up to $1B with Thermo Fisher Scientific (NYSE:TMO) on Tuesday to support the future commercial production of its pneumonia vaccines. Under the agreement, which Vaxcyte (NASDAQ:PCVX) cited as a key component in ...